when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ELI LILLY CO · news · pharmadog

← back to ELI LILLY CO

News mentioning ELI LILLY CO

630 stories

Aug 19, 26Takeda leads wave of orexin drugs with potential to upend narcolepsy marketbiospace

Aug 19, 26Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?biospace

Aug 18, 26AstraZeneca scores in lung cancer; Sandoz inks a China dealbiopharma dive

Aug 18, 26Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilarsbiospace

Aug 18, 26Rebounding biotech funds expected to spur CDMO growth within yearbiospace

Aug 18, 26Amylyx’s bet on a GLP-1 blocker pays offbiopharma dive

Aug 18, 26Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemiabiospace

Aug 18, 26STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle massstat

Aug 17, 26STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promisestat

Aug 17, 26EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD racebiospace

Aug 17, 26Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse mergerendpoints

Aug 17, 26STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefitstat

Aug 17, 26STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and morestat

Aug 17, 26Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trialsfiercebiotech

Aug 17, 26STAT+: Epic confronts unprecedented challenges as it prepares to address customers and unveil road mapstat

Aug 17, 26STAT+: UnitedHealth faces IRS probe over potential tax avoidancestat

Aug 17, 26Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vaguefiercebiotech

Aug 14, 26STAT+: PBMs agree to display TrumpRx drug pricesstat

Aug 14, 26Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myersbiopharma dive

Aug 14, 26STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug classstat

Aug 14, 26Biotech initiatives pick up as more regions race to become hubsbiopharma dive

Aug 14, 26How will legal challenges fare against CMS rule on gender-affirming care?stat

Aug 14, 26Nascent US psychedelic therapy opportunity attracts overseas manufacturersbiospace

Aug 13, 26PTC takes a chance on Sangamo’s Fabry disease gene therapybiopharma dive

Aug 13, 26STAT+: Eli Lilly targets booming black market for retatrutidestat

Aug 13, 26STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and morestat

Aug 13, 26Bankrupt Sangamo offloads assets to Lilly, PTC in $161M salebiospace

Aug 13, 26PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auctionendpoints

Aug 13, 26PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry marketfiercebiotech

Aug 12, 26Eli Lilly files first lawsuits over retatrutide 'black market'endpoints

← prevpage 11 of 21next →